Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I (NCT00001905) | Clinical Trial Compass
CompletedPhase 2
Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I
United States5 participantsStarted 1999-04
Plain-language summary
This study will evaluate the safety and effectiveness of the drug, interferon gamma, in treating leukocyte adhesion deficiency type I (LAD I). Patients with this inherited immune disorder do not have enough proteins called adhesion molecules on their infection-fighting white blood cells, impairing the ability of these cells to get to the site of infection. As a result, patients have recurrent infections of soft tissues, such as the skin, gums and gastrointestinal tract, and poor wound healing. Infants with severe LAD I often die from multiple infections. Interferon gamma may increase the number of adhesion molecules on white blood cells, and thus improve their function.
Patients with LAD I who weigh more than 13 kilograms (28.5 pounds) may be eligible for this study. Candidates will have personal and family medical histories taken, a physical examination, blood and urine tests and a chest X-ray or computed tomography (CT) scan.
Participants will receive injections of interferon gamma under the skin 3 times a week for 3 months. Adult patients will be taught how to give their own injections (similar to insulin injections for diabetes) and parents will be taught how to administer the shots to their child. Blood samples, usually be between 30 to 90 milliliters (2 to 6 tablespoons), will be drawn just before starting medication and again 1 day, 1 week, 1 month, 3 months and 4 months after therapy begins. At these same time intervals, patients will provide a salt-water mouth rinse specimen, which will be tested for changes in the number of white blood cells during interferon gamma treatment.
Patients will be admitted to the NIH Clinical Center for inpatient evaluations at the start of therapy and again after 1 week, 1month, 3 months and 4 months. The initial screening visit will take a few days and subsequent visits will take 1 to 2 days.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
PARTICIPANT INCLUSION CRITERIA:
Leukocyte Adhesion Deficiency type I, as determined by flow cytometry showing less than 10% CD18 expression in association with typical signs of LAD I .
Weight adequate to permit the blood drawing requirements of the protocol, greater than 13 kg.
Patients should be without serious, ongoing, uncontrolled infections.
Adequate hematopoietic, renal and hepatic function, defined as:
Absolute neutrophil count greater than or equal to 1500/microL;
Hemoglobin greater than or equal to 7g/dL (post transfusion or erythropoeitin);
Platelet count greater than or equal to 100,000/microL;
Creatinine less than or equal to 1.5 x upper limit of normal;
Bilirubin less than or equal to 1.5 x upper limit of normal;
AST/SGOT less than or equal to 2.5 x upper limit of normal;
ALT/SGPT less than or equal to 2.5 x upper limit of normal;
Calculated Creatinine Clearance greater than or equal to 60 mL/min.
Karnofsky Performance Status Index greater than or equal to 70.
Written signed informed consent.
PARTICIPANT EXCLUSION CRITERIA:
HIV infection.
Active malignancy.
Symptomatic cardiac disease or ongoing treatment for same.
Pregnant or lactating women.
Surgery during the two weeks prior to the start of IFN-gamma dosing.
Concurrent use of systemic corticosteroids, except for physiologic replacement.
Exposure to any investigational drug within four weeks prior to the start of dosing.
Any other major illness which, in the investigator's judgement, may …
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Trial details
NCT IDNCT00001905
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)